Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Juli 2022 20:40 ET | Quelle: Mesoblast Limited

Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management

NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L,...
09. Juni 2022 07:00 ET | Quelle: Mesoblast Limited

Mesoblast Key Opinion Leader Event Series for Investors & Analysts

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the...
31. Mai 2022 20:15 ET | Quelle: Mesoblast Limited

Operational Highlights and Financial Results for the Period Ended March 31, 2022

NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
28. April 2022 20:35 ET | Quelle: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
23. März 2022 20:40 ET | Quelle: Mesoblast Limited

Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board

NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip R....
24. Februar 2022 17:30 ET | Quelle: Mesoblast Limited

Operational Highlights and Financial Results for the Period Ended December 31, 2021

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
24. Februar 2022 05:57 ET | Quelle: Mesoblast Limited

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
20. Februar 2022 18:19 ET | Quelle: Mesoblast Limited

Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn’s Colitis After Direct Injection of Remestemcel-L by Colonoscopy

NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from...
01. Februar 2022 19:20 ET | Quelle: Mesoblast Limited

Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment...
30. Januar 2022 19:16 ET | Quelle: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, Jan. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational and...

Vorherige Seite

Nächste Seite